Search:

Partnership opportunities

Our technology in action

Patient information

CME Webcast featuring Dr. Poon on Recent Advances in Management of Hepatocellular Carcinoma

Recurrent Breast Cancer Clinical Trial Video

The Dignity Study Website

Contact us

Timelines

Clinical Pipeline

1. Lead indication for ThermoDox^® (Primary Liver Cancer)
   • Pivotal Phase III HCC agreed - January 2008; study sites, including China; primary end point is progression-free survival
2. Second indication for ThermoDox (RCW)
   • Phase I enrolling to establish MTD, anticipate this study will establish a safe and useful dose by the third quarter of 2008. Demonstrated biological activity (complete local response) at 30 mg/m² in patient population.
   • Pivotal multi-site RCW trial to be initiated in late 2008.

Complete Product Pipeline